{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T23:01:20Z","timestamp":1772233280318,"version":"3.50.1"},"reference-count":49,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2005,5,1]],"date-time":"2005-05-01T00:00:00Z","timestamp":1114905600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100004328","name":"Genentech Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"crossref"}]},{"name":"OSI Pharmaceuticals Inc."},{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2005,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Learning Objectives<\/jats:title>\n                    <jats:p>After completing this course, the reader will be able to: Describe the clinical and pathological characteristics of the cutaneous rash secondary to anti-EGFR therapy.Explain the prognostic implications of the cutaneous rash secondary to anti-EGFR therapy.Discuss the treatment of the cutaneous rash secondary to anti-EGFR therapy.<\/jats:p>\n                    <jats:p>Access and take the CME test online and receive 1 hour of AMA PRA category 1 credit at CME.TheOncologist.com<\/jats:p>\n                    <jats:p>Skin rash associated with HER1\/epidermal growth factor receptor (EGFR) inhibitors is common. The lack of clinical and patient guidance for this often chronic and sometimes distressing side effect makes rash management and etiology investigation high priorities. To address this, oncologists and dermatologists with experience with HER1\/EGFR inhibitors attended the HER1\/EGFR Inhibitor Rash Management Forum. Recommendations include continued analysis of the correlation between rash and clinical outcome and improving the accuracy and reproducibility of terminology and grading systems. Because acne vulgaris has a unique pathology, and the pathology and etiology of rash are unclear yet distinct from acne vulgaris, using such terms as acne, acne-like, or acneiform should be avoided. Until there is a specific dermatological definition, rash is best described using phenotypic terms for its appearance and location. It is currently unknown which agents are best for treating rash. Clinical trials of rash treatments are urgently required, and suggestions for agents to consider are made based on current knowledge. The effect of dose reduction or interruption on rash should also be investigated. Secondarily infected rash may be more frequent than has been previously recognized, and some investigators favor empiric use of an oral antibiotic if this appears to be the case. Suggestions for patients include makeup to camouflage the rash and an emollient to prevent and alleviate skin dryness. The increasing use of HER1\/EGFR-targeted agents makes managing rash important. We hope the outcomes from this Forum provide background for future studies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1634\/theoncologist.10-5-345","type":"journal-article","created":{"date-parts":[[2005,4,25]],"date-time":"2005-04-25T19:17:54Z","timestamp":1114456674000},"page":"345-356","source":"Crossref","is-referenced-by-count":219,"title":["HER1\/EGFR Inhibitor-Associated Rash: Future Directions for Management and Investigation Outcomes from the HER1\/EGFR Inhibitor Rash Management Forum"],"prefix":"10.1093","volume":"10","author":[{"given":"Rom\u00e1n","family":"P\u00e9rez-Soler","sequence":"first","affiliation":[{"name":"Montefiore Medical Center\/Albert Einstein College of Medicine, Bronx, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean Pierre","family":"Delord","sequence":"additional","affiliation":[{"name":"Institut Claudius Regaud, Toulouse, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allan","family":"Halpern","sequence":"additional","affiliation":[{"name":"Memorial Sloan-Kettering Cancer Center, New York, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Kelly","sequence":"additional","affiliation":[{"name":"University of Colorado Health Sciences Center, Denver, Colorado, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Krueger","sequence":"additional","affiliation":[{"name":"The Rockefeller University, Dermatology Laboratory, New York, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bartomeu Massut\u00ed","family":"Sureda","sequence":"additional","affiliation":[{"name":"Servicio Oncologi\u00e1 M\u00e9dica, Hospital General Universitario Alicante, Alicante, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joachim","family":"von Pawel","sequence":"additional","affiliation":[{"name":"Asklepios Fachkliniken, Gauting-Munich, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Temel","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salvatore","family":"Siena","sequence":"additional","affiliation":[{"name":"Divisione Oncologia Medica Falck, Ospedale Niguarda C\u00e1 Granda, Milano, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denis","family":"Souli\u00e8res","sequence":"additional","affiliation":[{"name":"Centre d'Oncologie, CHUM Campus Notre-Dame, Montreal, Quebec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonard","family":"Saltz","sequence":"additional","affiliation":[{"name":"Memorial Sloan-Kettering Cancer Center, New York, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Leyden","sequence":"additional","affiliation":[{"name":"University of Pennsylvania Hospital, Malvern, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2005,5,1]]},"reference":[{"key":"2021122209434168700_R1","doi-asserted-by":"crossref","first-page":"7022","DOI":"10.1200\/jco.2004.22.90140.7022","article-title":"A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1st line or 2nd line chemotherapy. A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial","volume":"23","author":"Shepherd","year":"2004","journal-title":"Proc Am Soc Clin Oncol"},{"key":"2021122209434168700_R2","first-page":"196","article-title":"Rash severity is predictive of increased survival with erlotinib HCI","volume":"22","author":"Clark","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"2021122209434168700_R3","first-page":"204","article-title":"The presence and intensity of the cetuximab-induced acne-like rash predicts increased survival in studies across multiple malignancies","volume":"22","author":"Saltz","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"2021122209434168700_R4","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1200\/JCO.2002.10.112","article-title":"ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial","volume":"20","author":"Ranson","year":"2002","journal-title":"J Clin Oncol"},{"key":"2021122209434168700_R5","doi-asserted-by":"crossref","first-page":"3815","DOI":"10.1200\/JCO.2002.03.038","article-title":"Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial","volume":"20","author":"Herbst","year":"2002","journal-title":"J Clin Oncol"},{"key":"2021122209434168700_R6","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.1200\/JCO.2001.19.13.3267","article-title":"Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies","volume":"19","author":"Hidalgo","year":"2001","journal-title":"J Clin Oncol"},{"key":"2021122209434168700_R7","doi-asserted-by":"crossref","DOI":"10.1111\/j.1525-1438.2005.00137.x","article-title":"Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1\/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study","volume-title":"Int J Gynecol Oncol","author":"Gordon"},{"key":"2021122209434168700_R8","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1200\/JCO.2004.10.182","article-title":"Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor","volume":"22","author":"Saltz","year":"2004","journal-title":"J Clin Oncol"},{"key":"2021122209434168700_R9","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1200\/JCO.2003.10.038","article-title":"Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer","volume":"21","author":"Fukuoka","year":"2003","journal-title":"J Clin Oncol"},{"key":"2021122209434168700_R10","first-page":"378","article-title":"Results of a phase I trial of the humanized anti epidermal growth factor receptor (EGFR) monoclonal antibody EMD 72000 in patients with EGFR expressing solid tumors","volume":"20","author":"Tewes","year":"2001","journal-title":"Proc Am Soc Clin Oncol"},{"key":"2021122209434168700_R11","volume-title":"Erbitux\u00ae [package insert] Cetuximab prescribing information","year":"2004"},{"key":"2021122209434168700_R12","doi-asserted-by":"crossref","first-page":"3234","DOI":"10.1200\/JCO.2001.19.13.3234","article-title":"Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer","volume":"19","author":"Robert","year":"2001","journal-title":"J Clin Oncol"},{"key":"2021122209434168700_R13","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1001\/jama.290.16.2149","article-title":"Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial","volume":"290","author":"Kris","year":"2003","journal-title":"JAMA"},{"key":"2021122209434168700_R14","first-page":"3766s","article-title":"Acne-like rash predicts response in patients treated with Cetuximab (IMC-C225) plus Irinotecan (CPT-11) in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR)","volume":"7","author":"Saltz","year":"2001","journal-title":"Clin Cancer Res"},{"key":"2021122209434168700_R15","first-page":"225","article-title":"Phase I and pharmacokinetic (PK) study of oral GW572016, a potent reversible dual inhibitor of both erbB1 and erbB2 tyrosine kinase (TK), administered in combination with capecitabine","volume":"22","author":"De Bono","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"2021122209434168700_R16","doi-asserted-by":"crossref","first-page":"3238","DOI":"10.1200\/JCO.2004.11.057","article-title":"Determinants of tumor response and survival with erlotinib","volume":"22","author":"Perez-Soler","year":"2004","journal-title":"J Clin Oncol"},{"key":"2021122209434168700_R17","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1200\/JCO.2004.06.075","article-title":"Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck","volume":"22","author":"Soulieres","year":"2004","journal-title":"J Clin Oncol"},{"key":"2021122209434168700_R18","volume-title":"Iressa\u00ae [package insert] Gefitnib prescribing information","year":"2004"},{"key":"2021122209434168700_R19","first-page":"256","article-title":"Multicenter study of ABX-EGF monotherapy in patients with metastatic colorectal cancer","volume":"22","author":"Meropol","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"2021122209434168700_R20","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1046\/j.1365-2133.2002.04864.x","article-title":"Follicular and epidermal alterations in patients treated with ZD1839 (Iressa), an inhibitor of the epidermal growth factor receptor","volume":"147","author":"Van Doorn","year":"2002","journal-title":"Br J Dermatol"},{"key":"2021122209434168700_R21","doi-asserted-by":"crossref","first-page":"7022","DOI":"10.1200\/jco.2004.22.90140.7022","article-title":"A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1st line or 2nd line chemotherapy. A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial","volume":"23","author":"Shepherd","year":"2004","journal-title":"Proc Am Soc Clin Oncol"},{"key":"2021122209434168700_R22","article-title":"Skin toxicity is not a clinically meaningful prognostic marker for tumour response to gefitinib (\u2018Iressa\u2019; ZD1839) in pretreated patients with advanced non-small-cell lung cancer","volume-title":"Second International Symposium on Signal Transduction Modulators in Cancer Therapy","author":"Ranson","year":"2003"},{"key":"2021122209434168700_R23","first-page":"159a","article-title":"Cetuximab (C225) plus irinotecan (CPT-11) plus infusional 5FU-folinic acid (FA) is safe and active in metastatic colorectal cancer (MCRC), that expresses epidermal growth factor receptor (EGFR)","volume":"21","author":"Schoffski","year":"2002","journal-title":"Proc Am Soc Clin Oncol"},{"key":"2021122209434168700_R24","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1046\/j.1365-2133.2001.04226.x","article-title":"Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225","volume":"144","author":"Busam","year":"2001","journal-title":"Br J Dermatol"},{"key":"2021122209434168700_R25","doi-asserted-by":"crossref","first-page":"4651","DOI":"10.1200\/JCO.2003.04.169","article-title":"Complications of therapy and a diagnostic dilemma case. Case 2. Cutaneous toxicity induced by cetuximab","volume":"21","author":"Monti","year":"2003","journal-title":"J Clin Oncol"},{"key":"2021122209434168700_R26","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1067\/mjd.2002.124621","article-title":"Paronychia induced by cetuximab, an antiepidermal growth factor receptor antibody","volume":"47","author":"Boucher","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"2021122209434168700_R27","first-page":"559","article-title":"Acne-like rash predicts response in patients treated with cetuximab (IMC-C225) plus irinotecan (CPT-11) in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR)","volume-title":"Proc NCI-AACR-EORTC","author":"Saltz","year":"2001"},{"key":"2021122209434168700_R28","first-page":"2a","article-title":"Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR)","volume":"20","author":"Saltz","year":"2001","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"suppl 7","key":"2021122209434168700_R29","first-page":"57","article-title":"ABX-EGF, a fully human anti-epidermal growth factor receptor (EGFr) monoclonal antibody: phase II clinical trials in renal cell cancer (RCC)","volume":"38","author":"Rowinsky","year":"2002","journal-title":"Eur J Cancer"},{"key":"2021122209434168700_R30","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.lungcan.2003.12.014","article-title":"Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, \u2018Iressa\u2019) on an expanded access study","volume":"44","author":"Janne","year":"2004","journal-title":"Lung Cancer"},{"key":"2021122209434168700_R31","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1158\/1078-0432.CCR-03-0564","article-title":"United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tablets","volume":"10","author":"Cohen","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"suppl 2","key":"2021122209434168700_R32","doi-asserted-by":"crossref","first-page":"S249","DOI":"10.1016\/S0169-5002(03)92587-6","article-title":"Gefitinib (\u2018Iressa\u2019, ZD1839) monotherapy as a salvage regimen for previously treated advanced non-small-cell lung cancer (NSCLC)","volume":"41","author":"Park","year":"2003","journal-title":"Lung Cancer"},{"key":"2021122209434168700_R33","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1056\/NEJMoa033025","article-title":"Cetuximab monotherapy and cetuximab plus irmotecan in irinotecan-refractory metastatic colorectal cancer","volume":"351","author":"Cunningham","year":"2004","journal-title":"N Engl J Med"},{"key":"2021122209434168700_R34","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1200\/JCO.2004.08.110","article-title":"Phase II trial of gefitinib in recurrent glioblastoma","volume":"22","author":"Rich","year":"2004","journal-title":"J Clin Oncol"},{"issue":"suppl 6","key":"2021122209434168700_R35","doi-asserted-by":"crossref","first-page":"164S","DOI":"10.1111\/1523-1747.ep12876141","article-title":"The EGF\/TGF alpha receptor in skin","volume":"94","author":"King","year":"1990","journal-title":"J Invest Dermatol"},{"key":"2021122209434168700_R36","first-page":"505","article-title":"The EGF receptor\u2014an essential regulator of multiple epidermal functions","volume":"10","author":"Jost","year":"2000","journal-title":"Eur J Dermatol"},{"key":"2021122209434168700_R37","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0092-8674(00)00026-X","article-title":"The EGF receptor provides an essential survival signal for SOS-dependent skin tumor development","volume":"102","author":"Sibilia","year":"2000","journal-title":"Cell"},{"key":"2021122209434168700_R38","doi-asserted-by":"crossref","first-page":"10S","DOI":"10.1111\/1523-1747.ep12505661","article-title":"Epidermal growth factor\/transforming growth factor alpha receptors and psoriasis","volume":"95","author":"King","year":"1990","journal-title":"J Invest Dermatol"},{"key":"2021122209434168700_R39","doi-asserted-by":"crossref","first-page":"5216","DOI":"10.1002\/j.1460-2075.1995.tb00206.x","article-title":"Expression of a dominant negative mutant of epidermal growth factor receptor in the epidermis of transgenic mice elicits striking alterations in hair follicle development and skin structure","volume":"14","author":"Murillas","year":"1995","journal-title":"EMBO J"},{"key":"2021122209434168700_R40","first-page":"203","article-title":"Antitumor activity of the HER1\/EGFR-TK inhibitor Tarceva (erlotinib, OSI-774) in human tumor xenograft models","volume-title":"EORTC-NCI-AACR","author":"Higgins","year":"2002"},{"key":"2021122209434168700_R41","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1001\/archderm.138.1.129","article-title":"Follicular toxic effects of chimeric anti-epidermal growth factor receptor antibody cetuximab used to treat human solid tumors","volume":"138","author":"Kimyai-Asadi","year":"2002","journal-title":"Arch Dermatol"},{"issue":"suppl 16","key":"2021122209434168700_R42","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0093-7754(01)90283-0","article-title":"Pharmacodynamic studies with the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839","volume":"28","author":"Albanell","year":"2001","journal-title":"Semin Oncol"},{"key":"2021122209434168700_R43","doi-asserted-by":"crossref","first-page":"4292","DOI":"10.1200\/JCO.2002.03.100","article-title":"Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types","volume":"20","author":"Baselga","year":"2002","journal-title":"J Clin Oncol"},{"key":"2021122209434168700_R44","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1200\/JCO.2002.20.1.110","article-title":"Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition","volume":"20","author":"Albanell","year":"2002","journal-title":"J Clin Oncol"},{"key":"2021122209434168700_R45","doi-asserted-by":"crossref","first-page":"366","DOI":"10.3816\/CLC.2003.n.016","article-title":"Dermatologic side effects associated with gefitinib therapy: clinical experience and management","volume":"4","author":"Herbst","year":"2003","journal-title":"Clin Lung Cancer"},{"key":"2021122209434168700_R46","first-page":"443","article-title":"\u00c9ruptions acn\u00e9iformes induites par le c\u00e9tuximab","volume":"30","author":"Walon","year":"2003","journal-title":"Ann Dermatol Venereol"},{"key":"2021122209434168700_R47","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0169-5002(03)00079-5","article-title":"ZD1839, a novel, oral epidermal growth factor receptor-tyrosine kinase inhibitor, as salvage treatment in patients with advanced non-small cell lung cancer. Experience from a single center participating in a compassionate use program","volume":"40","author":"Pallis","year":"2003","journal-title":"Lung Cancer"},{"key":"2021122209434168700_R48","first-page":"638","article-title":"Management of cutaneous adverse effects during treatment with ZD1839 in advanced non-small cell lung cancer (NSCLC): surprising efficacy of early local treatment","volume":"23","author":"Cortesi","year":"2004","journal-title":"Proc Am Soc Clin Oncol"},{"key":"2021122209434168700_R49","volume-title":"Tarceva\u2122, data on file","year":"2004"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.10-5-345","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.10-5-345","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/10\/5\/345\/41852114\/oncolo_10_5_345.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/10\/5\/345\/41852114\/oncolo_10_5_345.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,22]],"date-time":"2021-12-22T12:01:05Z","timestamp":1640174465000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/10\/5\/345\/6387434"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,5,1]]},"references-count":49,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2005,5,1]]},"published-print":{"date-parts":[[2005,5,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.10-5-345","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.12361.469850","asserted-by":"object"}]},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2005,5,1]]},"published":{"date-parts":[[2005,5,1]]}}}